PBT434 Lowers Alpha-Synuclein and Prevents Neurodegeneration
Filed with ASX · · 3 pages · English
Alterity Therapeutics Ltd. on 6ix
Earlier from Alterity Therapeutics
- PBT434 presented at 13th International AD/PD Conference
- Half Year Accounts
- Business Update
- S&P DJ Indices Announces March Quarterly Review
- S&P DJ Indices Announces March Quarterly Rebalance
Later from Alterity Therapeutics
- Prana commences research collaboration with Takeda
- Appendix 4E and Annual Report
- Notice of Meeting/ Proxy Form
- Prospectus Supplement
- Prana receives $3 million R&D Tax Incentive Refund
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics